Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration.

Yousif AM, Ingangi V, Merlino F, Brancaccio D, Minopoli M, Bellavita R, Novellino E, Carriero MV, Carotenuto A, Grieco P.

Eur J Med Chem. 2018 Jan 1;143:348-360. doi: 10.1016/j.ejmech.2017.11.030. Epub 2017 Dec 1.

PMID:
29202399
2.

Mimicking Intermolecular Interactions of Tight Protein-Protein Complexes for Small-Molecule Antagonists.

Xu D, Bum-Erdene K, Si Y, Zhou D, Ghozayel MK, Meroueh SO.

ChemMedChem. 2017 Nov 8;12(21):1794-1809. doi: 10.1002/cmdc.201700572. Epub 2017 Oct 23.

PMID:
28960868
3.

Ginkgolic acids inhibit migration in breast cancer cells by inhibition of NEMO sumoylation and NF-κB activity.

Hamdoun S, Efferth T.

Oncotarget. 2017 May 23;8(21):35103-35115. doi: 10.18632/oncotarget.16626.

4.

Small Molecules Engage Hot Spots through Cooperative Binding To Inhibit a Tight Protein-Protein Interaction.

Liu D, Xu D, Liu M, Knabe WE, Yuan C, Zhou D, Huang M, Meroueh SO.

Biochemistry. 2017 Mar 28;56(12):1768-1784. doi: 10.1021/acs.biochem.6b01039. Epub 2017 Mar 17.

5.

A novel homozygous mutation disrupting the initiation codon in the SLURP1 gene underlies mal de Meleda in a consanguineous family.

Shah K, Nasir A, Irfanullah, Shahzad S, Khan S, Ahmad W.

Clin Exp Dermatol. 2016 Aug;41(6):675-679. doi: 10.1111/ced.12864. Epub 2016 Jul 5.

PMID:
29226984
6.

Active site-directed plasmin inhibitors: Extension on the P2 residue.

Hidaka K, Gohda K, Teno N, Wanaka K, Tsuda Y.

Bioorg Med Chem. 2016 Feb 15;24(4):545-53. doi: 10.1016/j.bmc.2015.12.009. Epub 2015 Dec 8.

PMID:
26732532
7.

[Supercomputer investigation of the protein-ligand system low-energy minima].

Oferkin IV, Sulimov AV, Katkova EV, Kutov DK, Grigoriev FV, Kondakova OA, Sulimov VB.

Biomed Khim. 2015 Nov-Dec;61(6):712-6. doi: 10.18097/PBMC20156106712. Russian.

PMID:
26716742
8.

Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.

Gladysz R, Adriaenssens Y, De Winter H, Joossens J, Lambeir AM, Augustyns K, Van der Veken P.

J Med Chem. 2015 Dec 10;58(23):9238-57. doi: 10.1021/acs.jmedchem.5b01171. Epub 2015 Dec 1.

PMID:
26575094
9.

Molecular modeling as a new approach to the development of urokinase inhibitors.

Beloglazova IB, Plekhanova OS, Katkova EV, Rysenkova KD, Stambol'skii DV, Sulimov VB, Tkachuk VA.

Bull Exp Biol Med. 2015 Mar;158(5):700-4. doi: 10.1007/s10517-015-2839-3. Epub 2015 Mar 17.

PMID:
25778664
10.

Application of molecular modeling to urokinase inhibitors development.

Sulimov VB, Katkova EV, Oferkin IV, Sulimov AV, Romanov AN, Roschin AI, Beloglazova IB, Plekhanova OS, Tkachuk VA, Sadovnichiy VA.

Biomed Res Int. 2014;2014:625176. doi: 10.1155/2014/625176. Epub 2014 May 20.

11.

Ab initio molecular simulations for proposing novel peptide inhibitors blocking the ligand-binding pocket of urokinase receptor.

Mizushima T, Sugimoto T, Kasumi T, Araki K, Kobayashi H, Kurita N.

J Mol Model. 2014 Jun;20(6):2292. doi: 10.1007/s00894-014-2292-7. Epub 2014 May 25.

PMID:
24859527
12.

In silico interaction of methyl isocyanate with immune protein responsible for Mycobacterium tuberculosis infection using molecular docking.

Shrivastava R, Yasir M, Tripathi M, Singh P.

Toxicol Ind Health. 2016 Jan;32(1):162-7. doi: 10.1177/0748233713498447. Epub 2013 Sep 30.

PMID:
24081639
13.

Potential role of kringle-integrin interaction in plasmin and uPA actions (a hypothesis).

Takada Y.

J Biomed Biotechnol. 2012;2012:136302. doi: 10.1155/2012/136302. Epub 2012 Oct 16.

14.

Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.

Wang F, Eric Knabe W, Li L, Jo I, Mani T, Roehm H, Oh K, Li J, Khanna M, Meroueh SO.

Bioorg Med Chem. 2012 Aug 1;20(15):4760-73. doi: 10.1016/j.bmc.2012.06.002. Epub 2012 Jun 12.

15.

Polyphenol fatty acid esters as serine protease inhibitors: a quantum-chemical QSAR analysis.

Viskupicova J, Danihelova M, Majekova M, Liptaj T, Sturdik E.

J Enzyme Inhib Med Chem. 2012 Dec;27(6):800-9. doi: 10.3109/14756366.2010.616860. Epub 2011 Oct 10.

PMID:
21981000
16.

Urokinase plasminogen activator regulates pulmonary arterial contractility and vascular permeability in mice.

Nassar T, Yarovoi S, Fanne RA, Waked O, Allen TC, Idell S, Cines DB, Higazi AA.

Am J Respir Cell Mol Biol. 2011 Nov;45(5):1015-21. doi: 10.1165/rcmb.2010-0302OC. Epub 2011 May 26.

17.

Virtual screening using molecular simulations.

Yang T, Wu JC, Yan C, Wang Y, Luo R, Gonzales MB, Dalby KN, Ren P.

Proteins. 2011 Jun;79(6):1940-51. doi: 10.1002/prot.23018. Epub 2011 Apr 12.

18.

Regulation of airway contractility by plasminogen activators through N-methyl-D-aspartate receptor-1.

Nassar T, Yarovoi S, Fanne RA, Akkawi S, Jammal M, Allen TC, Idell S, Cines DB, Higazi AA.

Am J Respir Cell Mol Biol. 2010 Dec;43(6):703-11. doi: 10.1165/rcmb.2009-0257OC. Epub 2010 Jan 22.

19.

Comparative binding energy analysis for binding affinity and target selectivity prediction.

Henrich S, Feierberg I, Wang T, Blomberg N, Wade RC.

Proteins. 2010 Jan;78(1):135-53. doi: 10.1002/prot.22579.

PMID:
19768680
20.

In silico docking of urokinase plasminogen activator and integrins.

Degryse B, Fernandez-Recio J, Citro V, Blasi F, Cubellis MV.

BMC Bioinformatics. 2008 Mar 26;9 Suppl 2:S8. doi: 10.1186/1471-2105-9-S2-S8.

Supplemental Content

Loading ...
Support Center